Transplant in the Elderly Population
This session will focus on considerations and outcomes of allo-HSCT specifically among patients over 55 years of age. The panel will discuss how transplant protocols and supportive care measures can be optimized for this population who are at higher risk of comorbidities, toxicity and poor functional status.
Optimizing Outcomes Allogeneic Transplants Hematologic Malignancies Allo Hsct Allo Transplant Allogeneic Transplant
Source: onclive.com